<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433719</url>
  </required_header>
  <id_info>
    <org_study_id>OXTREC 023-04</org_study_id>
    <secondary_id>ISRCTN63659091</secondary_id>
    <nct_id>NCT00433719</nct_id>
  </id_info>
  <brief_title>Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis</brief_title>
  <official_title>Randomised Controlled Trial of Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal time to initiate antiretroviral therapy (ART) in HIV-associated tuberculous&#xD;
      meningitis (TBM) unknown. There are concerns that immediate ART may worsen rather than&#xD;
      improve outcome, because drug interactiond and toxicities or development of an intracerebral&#xD;
      immune reconstitution inflammatory syndrome (IRIS). Conversely, delaying ART may result in&#xD;
      increased HIV-related deaths. To answer this question, we are conducting a randomised,&#xD;
      double-blind placebo-controlled trial comparing immediate and deferred ART in HIV-infected&#xD;
      patients presenting with TBM, to assess effect on survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Study of immediate versus deferred antiretroviral therapy in HIV-associated&#xD;
      tuberculous meningitis Study design: A randomized, double blind, placebo-controlled trial&#xD;
      with 2 parallel arms Sample size: 247 Inclusion criteria: Age 15 years or older; HIV antibody&#xD;
      positive; clinical diagnosis of TBM.&#xD;
&#xD;
      Exclusion criteria: positive CSF Gram or India ink stain, known or suspected pregnancy;&#xD;
      antituberculous treatment 8 to 30 days immediately prior to recruitment; previous&#xD;
      antiretroviral therapy; laboratory contraindications to antiretroviral or antituberculous&#xD;
      therapy; lack of consent.&#xD;
&#xD;
      Consent: Written informed consent will be sought for all patients. Verbal consent will be&#xD;
      considered acceptable when written consent is impossible. In unconscious patients, the&#xD;
      consent of 2 independent physicians will be considered acceptable.&#xD;
&#xD;
      Randomization: Patients will be stratified according to TBM disease severity at presentation&#xD;
      (modified MRC grade I to III). Within each stratum, patients will be randomized to 1 of the 2&#xD;
      treatment arms: immediate or deferred (2 months) ART.&#xD;
&#xD;
      Antituberculous treatment: Initial therapy will be with isonazid, rifampicin, pyrazinamide&#xD;
      and ethambutol for 3 months. After 3 months, patients will continue on rifampicin and&#xD;
      isoniazid for a further 6 months.&#xD;
&#xD;
      Corticosteroid treatment: Dexamethasone 0.3 - 0.4mg/kg will be administered and tapered over&#xD;
      6 - 8 weeks, according to TBM grade.&#xD;
&#xD;
      Antiretrovira l treatment: Antiretrovirals (zidovudine, lamivudine and efavirenz)or identical&#xD;
      placebo tablets will be commenced at study entry and continued for 2 months. Thereafter, all&#xD;
      patients will received antiretrovirals.&#xD;
&#xD;
      Clinical monitoring: Patients will be assessed weekly as an inpatient for 3 months. Hospital&#xD;
      outpatient review will occur monthly until 9 months. A final follow-up visit will take place&#xD;
      at 12 months.&#xD;
&#xD;
      Laboratory monitoring: Routine laboratory tests will be monitored weekly as an inpatient and&#xD;
      monthly as an outpatient. Blood samples for CD4 T-lymphocyte count and plasma HIV-1 RNA level&#xD;
      will be monitored 3-monthly. CSF samples will be taken at 0, 1, 2, 3, 6 and 9 months.&#xD;
&#xD;
      Radiology: Patients will have a chest radiograph performed on admission. A CT or MRI brain&#xD;
      scan may also be performed if clinically indicated.&#xD;
&#xD;
      Adverse events: All grade 3 and 4 adverse events will be reported immediately to the Data and&#xD;
      Safety Monitoring Committee.&#xD;
&#xD;
      Outcome measures: The primary endpoint will be mortality at 9 months. The secondary endpoints&#xD;
      will be: mortality at 12 months; fever clearance time; coma clearance time; neurological&#xD;
      relapse; progression to new or recurrent AIDS defining illness; any grade 3 or 4 adverse&#xD;
      event; CD4 count response; plasma HIV-1 RNA response; neurological disability.&#xD;
&#xD;
      Data analysis: Analysis will be based on intention to treat.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever clearance time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coma clearance time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma HIV RNA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 adverse event</measure>
    <time_frame>Any</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological disability</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculous Meningitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combivir, efavirenz for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 2 months followed by Combivir and efavirenz for 10 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combivir and efavirenz</intervention_name>
    <description>Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 15 years or older&#xD;
&#xD;
          -  HIV antibody positive&#xD;
&#xD;
          -  clinical diagnosis of TB meningitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  positive CSF Gram or India ink stain&#xD;
&#xD;
          -  known or suspected pregnancy&#xD;
&#xD;
          -  antituberculous treatment 8 - 30 days immediately prior to recruitment&#xD;
&#xD;
          -  previous antiretroviral therapy&#xD;
&#xD;
          -  laboratory contraindications to antiretroviral or antituberculous therapy&#xD;
&#xD;
          -  lack of consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Estee Torok</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Tropical Diseases</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pham Ngoc Thach Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>August 6, 2008</last_update_submitted>
  <last_update_submitted_qc>August 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Centre for Tropical Diseases</name_title>
    <organization>University of Oxford</organization>
  </responsible_party>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>Tuberculous meningitis</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Meningeal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

